9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

      American Journal of Transplantation

      blood, genetics, TRPP Cation Channels, TOR Serine-Threonine Kinases, therapeutic use, Sirolimus, antagonists & inhibitors, Protein-Serine-Threonine Kinases, pathology, drug therapy, Polycystic Kidney, Autosomal Dominant, Male, Magnetic Resonance Imaging, Liver Transplantation, Kidney Transplantation, Introns, Intracellular Signaling Peptides and Proteins, Immunosuppressive Agents, Immunohistochemistry, Humans, Female, Exons, Creatinine, Blotting, Western, Adult

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models. The optimal therapeutic dose of sirolimus is not yet defined. Here, we report the history of a previously unknown ADPKD deceased donor whose kidneys were engrafted in two different recipients. One of the two received an immunosuppressive regimen based on sirolimus for 5 years while the other did not. After transplantation, both patients developed severe transplant cystic disease. Donor DNA sequence identified a new hypomorphic mutation in PKD1. The rate of cyst growth was identical in the two patients regardless of the treatment. While sirolimus treatment reduced the activation of mTOR in peripheral blood mononuclear cells, it failed to prevent mTOR activation in kidney tubular cells, this could account for the inefficiency of treatment on cyst growth. Together, our results suggest that the dose of sirolimus required to inhibit mTOR varies according to the tissue.

          Related collections

          Author and article information

          Journal
          20642692
          3697013
          10.1111/j.1600-6143.2010.03152.x

          Comments

          Comment on this article